Agrawal Rupesh, Gupta Bhaskar, Gonzalez-Lopez Julio J, Rahman Farzana, Phatak Sumita, Triantafyllopoulou Ioanna, Addison Peter K F, Westcott Mark, Pavesio Carlos E
Moorfields Eye Hospital, NHS Foundation Trust , London , UK .
Ocul Immunol Inflamm. 2015 Feb;23(1):40-6. doi: 10.3109/09273948.2014.986584.
To analyze the factors affecting the treatment outcome in patients with presumed ocular tuberculosis on anti-tubercular therapy (ATT).
Retrospective chart review of patients with presumed ocular tuberculosis seen at a tertiary referral eye care center in the United Kingdom. Failure was defined as recurrence of inflammation within 6 months of completion of ATT.
There were a total of 175 patients with presumed ocular tuberculosis who had ATT. Patients with intermediate uveitis or panuveitis and those on immunosuppressive therapy had higher odds of treatment failure (p < 0.05) while those with more than 9 months of ATT (77, 79.38%) had less likelihood of failure.
We present the largest case series of patients with presumed ocular tuberculosis in a low endemic area treated with ATT. Longer duration of treatment resulted in reduced risk of recurrence of inflammation, whereas immunosuppression adversely affected the final treatment outcome.
分析抗结核治疗（ATT）对疑似眼部结核患者治疗结局的影响因素。
对英国一家三级转诊眼科护理中心的疑似眼部结核患者进行回顾性病历审查。治疗失败定义为ATT完成后6个月内炎症复发。
共有175例疑似眼部结核患者接受了ATT。中间葡萄膜炎或全葡萄膜炎患者以及接受免疫抑制治疗的患者治疗失败几率更高（p<0.05），而接受ATT超过9个月的患者（77例，79.38%）失败可能性较小。
我们展示了在低流行地区接受ATT治疗的疑似眼部结核患者的最大病例系列。治疗时间延长可降低炎症复发风险，而免疫抑制对最终治疗结局有不利影响。
